Brought to you by 
Fate Therapeutics launched through $14.6mm Series A
20 Apr 2009
Executive Summary
Fate Therapeutics (adult stem cell biology) was recently launched through a two-tranche $14.6mm Series A round backed by Arch Venture Partners, Polaris Venture Partners, OVP Venture Partners, and Venrock. The start-up has a small-molecule platform that modulates adult stem cells to mimic the beneficial characteristics of embryonic stem cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fate Therapeutics launched through $14.6mm Series A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice